Adenosine as an Adjunct to Blood Cardioplegia

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

Also called NCT02681913

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 2
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT02681913
  • EudraCT 2015-001923-22
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Netherlands (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02681913. Randomized; quadruple masking; primary purpose prevention. Start 2016-02 (registry gives no type); primary completion 2018-07 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Adenosine as an Adjunct to Blood Cardioplegia
Condition
Pathological Processes
Condition
Cardiomyopathies
Intervention (Drug)
Adenosine
Lead sponsor
Amphia Hospital (class: other)

Record details

Record id
cardio:ct-nct02681913
Content hash
1224bc0ae22279f06936543ab0046743c638441c32665f086c3d6c5fa3be19f8